Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Luspatercept [USAN:INN]
RN: 1373715-00-4
UNII: AQK7UBA1LS

Note

  • NCI: A soluble, recombinant fusion protein composed of a modified form of the extracellular domain of human activin receptor type IIb (ActRIIb) and linked to the human IgG1 Fc domain, with red blood cell stimulating activity. Upon subcutaneous administration, ACE-536 inhibits several ligands in the transforming growth factor (TGF)-beta superfamily. This prevents activation of a variety of TGF-beta superfamily members involved in late stage erythropoiesis and results in an increased differentiation and proliferation of erythroid progenitors. ACE-536 acts at a different, later stage than erythropoietin. This agent ultimately enhances red blood cell production and prevents anemia. (NCI Thesaurus)

Molecular Formula

  • C3350-H5070-N906-O1044-S38
 

Classification Code

  • Treatment of Anemia Associated with Ineffective Erythropoiesis
* denotes mobile formatted website

Links to Resources

Names and Synonyms

Name of Substance

  • Luspatercept [USAN:INN]

Synonyms

  • ACE 536
  • ACE-536
  • Luspatercept
  • UNII-AQK7UBA1LS

Systematic Names

  • (79-L-aspartic acid(L>D))human activin receptor type-2B (ACTR-IIB, EC=2.7.11.30) precursor-(25-131)-peptide (extracellular domain fragment) fusion protein with triglycyl-human immunoglobulin heavy constant gamma 1 Fc fragment-(8-232)-peptide dimer (114-114':117-117')-bisdisulfide
  • Activin receptor type IIB (synthetic human extracellular domain 107-amino acid fragment) fusion protein with glycylglycylglycine fusion protein with immunoglobulin G1 (synthetic human Fc region 225-amino acid C-terminal fragment), dimer

Registry Numbers

CAS Registry Number

  • 1373715-00-4

FDA UNII

  • AQK7UBA1LS

System Generated Number

  • 1373715004